Lynk Pharmaceuticals' Topical JAK Inhibitor LNK01004 Shows Promising Phase II Results for Moderate-to-Severe Atopic Dermatitis
核心洞察
Lynk Pharmaceuticals (搜索) announced positive Phase II results for LNK01004, a topical JAK (搜索) inhibitor, demonstrating superior efficacy over placebo in treating moderate-to-severe atopic dermatitis (搜索).
The randomized, double-blind study of 75 patients showed EASI-75 response rates of 61.1% and 46.2% for the 0.3% and 1.0% doses respectively, compared to 20% for placebo in patients with BSA ≥10%.
LNK01004 demonstrated excellent safety profile with minimal systemic exposure and no treatment-related serious adverse events, positioning it as a promising alternative to systemic therapies.
Lynk Pharmaceuticals (搜索) Co., Ltd. announced encouraging Phase II clinical trial results for LNK01004, a skin-restricted, soft pan-JAK (搜索) inhibitor, demonstrating significant efficacy and favorable safety in treating moderate-to-severe atopic dermatitis (搜索). The topical formulation offers a promising alternative to systemic therapies currently relied upon for this challenging dermatological condition.
Study Design and Patient Population
The randomized, double-blind, vehicle-controlled Phase II study enrolled 75 adult patients with moderate-to-severe atopic dermatitis (搜索). Participants were randomized in a 1:1:1 ratio to receive LNK01004 0.3%, LNK01004 1.0%, or vehicle ointment twice daily for 8 weeks. Eligible patients had a validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of 3 or 4 and body surface area (BSA) involvement between 5% and 35%.
Efficacy Outcomes Show Dose-Dependent Response
After 8 weeks of treatment, both LNK01004 dose groups achieved higher EASI-75 response rates than the vehicle group, with particularly pronounced benefits observed in patients with higher baseline BSA involvement. Among patients with BSA ≥10%, the EASI-75 response rates were 61.1% for the 0.3% group, 46.2% for the 1.0% group, and 20% for the vehicle group.
The vIGA-AD response rates (score 0/1 with ≥2-point improvement) further supported the drug's efficacy, with rates of 44.4%, 38.5%, and 10% for the 0.3%, 1.0%, and vehicle groups respectively in the same patient population. Notably, patients with BSA ≥20% demonstrated even greater clinical improvements with both LNK01004 groups, reinforcing the drug's potential for treating more severe disease presentations.
Safety Profile Demonstrates Minimal Systemic Exposure
LNK01004 exhibited excellent tolerability with remarkably low systemic exposure following topical administration. Mean maximum plasma concentrations (Cmax) were 0.06 ng/mL and 0.15 ng/mL for the 0.3% and 1.0% groups respectively, representing levels hundreds of times lower than the human whole-blood IC50.
All treatment-related adverse events were classified as mild or moderate (Grade 1-2), and no treatment-related serious adverse events were observed throughout the study period. The safety profile remained consistent with findings from earlier clinical studies.
Clinical Significance and Development Strategy
"The Phase II results for LNK01004 demonstrated encouraging efficacy and favorable safety in patients with moderate-to-severe atopic dermatitis (搜索), particularly in those with larger affected areas or more severe disease," said Dr. Henry Wu, Chief Development Officer of Lynk Pharmaceuticals (搜索). "These findings highlight LNK01004 as a promising topical JAK (搜索) inhibitor and underscore its potential clinical value in dermatologic indications."
Dr. Zhao-Kui (ZK) Wan, Chairman and CEO of Lynk Pharmaceuticals (搜索), emphasized the clinical advantage of the topical approach: "Current treatment options for moderate-to-severe atopic dermatitis (搜索) often rely on systemic therapies. LNK01004, as a topical formulation, no systemic immunosuppression–related adverse reactions were observed in clinical studies, demonstrating good safety and compliance, as well as improvement in patients' quality of life."
Company Background and Future Plans
Lynk Pharmaceuticals (搜索), founded by senior drug R&D experts and executives from Pfizer, Merck (搜索), and Johnson & Johnson, focuses on discovering and developing innovative drugs for immune and inflammatory diseases. The company plans to continue advancing LNK01004's clinical development in atopic dermatitis (搜索) and explore its potential in other dermatological indications to address unmet medical needs globally.